Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib plus pembrolizumab versus pembrolizumab alone in first-line advanced NSCLC with high PD-L1 expression
NL-OMON49613Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Capmatinib + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: active, not recruiting.
02
Drugs
capmatinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49613.